Alison C Burggren1, Anaheed Shirazi2, Nathaniel Ginder2, Edythe D London2,3. 1. Robert and Beverly Lewis Center for Neuroimaging, University of Oregon, Eugene, OR, USA. 2. Department of Psychiatry and Biobehavioral Sciences, University of California at Los Angeles, Los Angeles, CA, USA. 3. Department of Molecular and Medical Pharmacology, and the Brain Research Institute, University of California at Los Angeles, Los Angeles, CA, USA.
Abstract
Background: Cannabis is the most widely used illicit substance worldwide, and legalization for recreational and medical purposes has substantially increased its availability and use in the United States. Objectives: Decades of research have suggested that recreational cannabis use confers risk for cognitive impairment across various domains, and structural and functional differences in the brain have been linked to early and heavy cannabis use. Methods: With substantial evidence for the role of the endocannabinoid system in neural development and understanding that brain development continues into early adulthood, the rising use of cannabis in adolescents and young adults raises major concerns. Yet some formulations of cannabinoid compounds are FDA-approved for medical uses, including applications in children. Results: Potential effects on the trajectory of brain morphology and cognition, therefore, should be considered. The goal of this review is to update and consolidate relevant findings in order to inform attitudes and public policy regarding the recreational and medical use of cannabis and cannabinoid compounds.Conclusions: The findings point to considerations for age limits and guidelines for use.
Background: Cannabis is the most widely used illicit substance worldwide, and legalization for recreational and medical purposes has substantially increased its availability and use in the United States. Objectives: Decades of research have suggested that recreational cannabis use confers risk for cognitive impairment across various domains, and structural and functional differences in the brain have been linked to early and heavy cannabis use. Methods: With substantial evidence for the role of the endocannabinoid system in neural development and understanding that brain development continues into early adulthood, the rising use of cannabis in adolescents and young adults raises major concerns. Yet some formulations of cannabinoid compounds are FDA-approved for medical uses, including applications in children. Results: Potential effects on the trajectory of brain morphology and cognition, therefore, should be considered. The goal of this review is to update and consolidate relevant findings in order to inform attitudes and public policy regarding the recreational and medical use of cannabis and cannabinoid compounds.Conclusions: The findings point to considerations for age limits and guidelines for use.
Entities:
Keywords:
Cannabis; brain; cannabidiol; cognition; endocannabinoid; medical marijuana; morphology; tetrahydrocannabinol
Authors: Nadia Solowij; Katy A Jones; Megan E Rozman; Sasha M Davis; Joseph Ciarrochi; Patrick C L Heaven; Dan I Lubman; Murat Yücel Journal: Psychopharmacology (Berl) Date: 2011-02-17 Impact factor: 4.530
Authors: Tashia Petker; Mark Ferro; Michael Van Ameringen; James Murphy; James MacKillop Journal: Psychopharmacology (Berl) Date: 2021-02-27 Impact factor: 4.530
Authors: Andrea H Weinberger; Jiaqi Zhu; Jacob Levin; Scott J Moeller; Sherry A McKee; Renee D Goodwin Journal: Alcohol Clin Exp Res Date: 2021-12-20 Impact factor: 3.455
Authors: Elizabeth J D'Amico; Anthony Rodriguez; Joan S Tucker; Michael S Dunbar; Eric R Pedersen; Rachana Seelam Journal: Drug Alcohol Depend Date: 2022-03-22 Impact factor: 4.852
Authors: Danielle C Hergert; Cidney Robertson-Benta; Veronik Sicard; Daniela Schwotzer; Kent Hutchison; Dan P Covey; Davin K Quinn; Joseph R Sadek; Jacob McDonald; Andrew R Mayer Journal: J Neurotrauma Date: 2021-01-25 Impact factor: 4.869
Authors: Jessica S Flannery; Michael C Riedel; Taylor Salo; Ranjita Poudel; Angela R Laird; Raul Gonzalez; Matthew T Sutherland Journal: Prog Neuropsychopharmacol Biol Psychiatry Date: 2021-07-03 Impact factor: 5.067